COVID-19 疫苗接种后消化道症状的意义:一项回顾性单中心研究
该回顾性单中心研究纳入 2021 年 3 月 1 日至 7 月 30 日接种 COVID-19 疫苗后出现消化道症状的 46 例韩国患者(男 22 例、女 24 例,中位年龄 68 岁,四分位距 55.5–73.8 岁),收集症状、实验室、影像、合并症、并发症、治疗与预后信息。接种疫苗为 AZD1222 33 例(71.7%)、BNT162b2 9 例(19.6%)、JNJ-78436735 3 例(6.5%)。按病情严重度分为轻度 25 例(54.3%)、中度 5 例(10.9%)、重度 16 例(34.8%)。消化道症状包括腹痛、腹泻、消化不良和恶心,通常于首次接种后 1 天内出现(78.3%)。14 例(30.4%)仅有胃肠道症状,32 例(69.6%)有非胃肠道症状。并发症包括肠炎(76%)、急性肾损伤(9%)、类过敏反应(2%)和十二指肠穿孔(2%)。作者认为监测接种后消化道症状有助于发现需要医疗干预的较重并发症,但需进一步验证。
要点
- 46 例接种 COVID-19 疫苗后出现消化道症状者中,重度 16 例(34.8%)、中度 5 例(10.9%)、轻度 25 例(54.3%)。
- 消化道症状包括腹痛、腹泻、消化不良和恶心,78.3% 在首次接种后 1 天内出现。
- 并发症包括肠炎(76%)、急性肾损伤(9%)、类过敏反应(2%)、十二指肠穿孔(2%)。
- 14 例(30.4%)仅有胃肠道症状,32 例(69.6%)同时有非胃肠道症状。
- 作者认为监测接种后消化道症状有助于发现需要医疗干预的较重并发症,但需进一步验证。
适用人群与场景
- 2021 年 3 月 1 日至 7 月 30 日接种 COVID-19 疫苗后出现消化道症状的韩国患者,共 46 例(男 22 例、女 24 例),中位年龄 68 岁(四分位距 55.5–73.8 岁)。
红旗征与不能漏的情况
- 并发症包括肠炎(76%)、急性肾损伤(9%)、类过敏反应(2%)和十二指肠穿孔(2%),作者认为监测消化道症状有助于发现需要医疗干预的较重并发症。
研究设计与关键结果
- 回顾性单中心研究,纳入 46 例接种 COVID-19 疫苗后出现消化道症状者,接种 AZD1222 33 例(71.7%)、BNT162b2 9 例(19.6%)、JNJ-78436735 3 例(6.5%)。
- 按病情严重度分为轻度 25 例(54.3%)、中度 5 例(10.9%)、重度 16 例(34.8%)。
- 消化道症状包括腹痛、腹泻、消化不良和恶心,通常于首次接种后 1 天内出现(78.3%)。
- 14 例(30.4%)仅有胃肠道症状,32 例(69.6%)有非胃肠道症状。
- 并发症包括肠炎(76%)、急性肾损伤(9%)、类过敏反应(2%)、十二指肠穿孔(2%)。
证据类型、等级与局限
- 证据类型:回顾性单中心研究。
- 局限:原文未报告局限性;作者在结论中写明需进一步验证。
对床旁实践的改变
- 作者认为,监测 COVID-19 疫苗接种后的消化道症状有助于发现需要医疗干预的较重并发症,但需进一步验证。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: There is insufficient research on digestive symptoms and outcomes following coronavirus disease (COVID-19) vaccination. We aimed to investigate digestive symptoms and related complications among South Koreans who were administered COVID-19 vaccines.
METHODS: Forty-six patients (men: 22, women: 24) with a median age of 68 years (interquartile range:55.5, 73.8 years) who experienced digestive symptoms following COVID-19 vaccination between March 1 and July 30, 2021, were included. This retrospective single-center study collected information on clinical symptoms, laboratory tests, imaging results, comorbidities, complications, treatment type, and prognosis.
RESULTS: Thirty-three (71.7%), nine (19.6%), and three (6.5%) patients were administered AZD1222 (AstraZeneca), BNT162b2 (Pfizer/BioNTech), and JNJ-78436735 (Johnson and Johnson) vaccines, respectively. Patients were classified with mild (25 patients, 54.3%), moderate (five patients, 10.9%), and severe (16 patients, 34.8%) based on disease severity. Digestive symptoms included abdominal pain, diarrhea, dyspepsia, and nausea, which usually developed within 1 day (78.3%) following the first vaccination. In total, 14 (30.4%) patients experienced only gastrointestinal symptoms, whereas 32 (69.6%) experienced non-gastrointestinal symptoms. Complications included enterocolitis (76%), acute kidney injury (9%), anaphylactoid reaction (2%), and duodenal perforation (2%).
CONCLUSIONS: COVID-19 vaccines caused digestive symptoms and other complications that ranged from mild to severe. While further validation is required, our results suggest that monitoring digestive symptoms following COVID-19 vaccination can help detect rather severe complications that require medical intervention.
参考来源
- Lee DS, Kim JW, Lee KL, et al. Significance of digestive symptoms after COVID-19 vaccination: A retrospective single-center study. Am J Emerg Med. 2022. PMID: 35691237. doi:10.1016/j.ajem.2022.05.044
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。